ROCKET: Phase II Randomized, Active-controlled, Multicenter Trial to Assess the Safety and Efficacy of RRx-001 + Irinotecan vs. Single-agent Regorafenib in Third/Fourth Line Colorectal Cancer.
Clin Colorectal Cancer
; 22(1): 92-99, 2023 03.
Article
in En
| MEDLINE
| ID: mdl-36529613
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colorectal Neoplasms
Type of study:
Clinical_trials
Limits:
Humans
Language:
En
Journal:
Clin Colorectal Cancer
Journal subject:
GASTROENTEROLOGIA
/
NEOPLASIAS
Year:
2023
Document type:
Article
Affiliation country:
Canada
Country of publication:
United States